SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Faderl S,Talpaz M,Estrov Z,O'Brien S,Kurzrock R,Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341: 164172.
  • 2
    Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340: 13301340.
  • 3
    Lee SJ. Chronic myeloid leukemia. Br J Hematol. 2000; 111: 9931009.
  • 4
    Savage DG,Szydlo RM,Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16 year period. Br J Hematol. 1997; 96: 111116.
  • 5
    Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290293.
  • 6
    Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol. 1988; 25: 2034.
  • 7
    Wang JYJ. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev. 1993; 3: 3543.
  • 8
    Savage DG,Antman KH. Imatinib mesylate—a new oral targeted therapy. N Engl J Med. 2002; 346: 683693.
  • 9
    Jahagirdar BN,Miller JS,Shet A,Verfaillie CM. Novel therapies for chronic myeloid leukemia. Exp Hematol. 2001; 29: 543556.
  • 10
    Savage DG,Goldman JM. Chronic myelogenous leukemia. In: ArmitageJO,AntmanKH, eds. High Dose Therapy: Pharmacology, Hematopoetins, Stem Cells. Baltimore, Md: Williams & Wilkins; 1999: 705731.
  • 11
    Bolin RW,Robinson WA,Sutherland J,Hamman RF. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer. 1982; 50: 16831686.
  • 12
    The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose-interferon-alpha 2bfor chronic myeloid leukemia. Blood. 1998; 91: 27132721.
  • 13
    Silver RT,Woolf SH,Hehlmann R, et al. An evidence-based analysis of the effect of busulphan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 2001; 94: 15171536.
  • 14
    Hehlmann R,Heimpel H,Hasford J, et al. Randomized comparison of interferon-alpha with busulphan and hydroxyurea in chronic myeloid leukemia. Blood. 1994; 84: 40644077.
  • 15
    Talpaz M,Kantarjian HM,McCredie K,Trujillo JM,Keating MJ,Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med. 1986; 314: 10651069.
  • 16
    Kantarjian HM,Smith TL,O'Brien S,Beran M,Pierce S,Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995; 122: 254261.
  • 17
    [No authors listed.] Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997; 89: 16161620.
  • 18
    Baccarani M,Rosti G,de Vivo A, et al. A randomized study of interferon α versus interferon α and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002; 99: 15271535.
  • 19
    Kantarjian HM,O'Brien S,Smith T, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999; 17: 284292.
  • 20
    Baccarani M,Russo D,Rosti G,Martinelli G. Interferon alpha for chronic myeloid leukemia. Semin Hematol. 2003; 40: 2233.
  • 21
    Baccarani M,Saglio G,Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108: 18091820.
  • 22
    Kantarjian HM,O'Brien S,Cortes J, et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long term prognosis. Cancer. 2003; 97: 10331041.
  • 23
    Mahon FX,Delbrel X,Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002; 20: 214220.
  • 24
    Bonifazi F,de Vivo A,Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001; 98: 30743081.
  • 25
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994; 330: 820825.
  • 26
    Allan NC,Richards SM,Shepherd PC. UK Medical Research Council randomized multicentre trial of interferon-alpha 1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response.The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. Lancet. 1995; 345: 13921397.
  • 27
    Ohnishi K,Ohno R,Tomonago M, et al. A randomized trial comparing interferon alpha with busulphan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995; 86: 906916.
  • 28
    Guilhot F,Chastang C,Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997; 337: 223229.
  • 29
    Goldman JM,Drucker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001; 98: 20392042.
  • 30
    Italian Cooperative Study Group on Chronic Myeloid Leukemia andItalian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol. 1999: 17: 18581868.
  • 31
    Simonsson B,Oberg G,Bjoreman M, et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long term follow-up. Acta Haematol. 2005; 113: 155162.
  • 32
    Kantarjian H,Sawyers C,Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 33
    Kantarjian HM,Cortes J,O'Brien S, et al. Long term survival benefit and improved complete cytogenetic and molecular response rate with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004; 104: 19791988.
  • 34
    Rosti G,Martinelli G,Bassi S, et al. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Blood. 2004; 103: 22842290.
  • 35
    Talpaz M,Silver RT,Drucker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses inpatients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 19281937.
  • 36
    Drucker BJ,Sawyers CL,Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 10381042.
  • 37
    Goldman JM,Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 10841086.
  • 38
    Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukemia: lessons to be learned from the laboratory. Br J Haematol. 2001; 113: 1123.
  • 39
    O'Brien SG,Guilhot F,Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 9941004.
  • 40
    Funke VAM,Medeiro CR,Lima DH, et al. Therapy of chronic myeloid leukemia with Imatinib mesylate in Brazil: a study of 98 cases. Rev Bras Hematol Hemoter. 2005; 27: 159165.
  • 41
    Farlay J,Bray F,Pisani P,Parkin DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Cancer Base No. 5. Lyon: IARC Press; 2001.
  • 42
    Kantarjian, HM,O'Brien S,Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003; 98: 26362642.
  • 43
    Kantarjian, HM,Talpaz M,O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—comparison with historic experience. Cancer. 2004; 103: 20992108.
  • 44
    Hahn EA,Glendenning GA,Sorenson MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alpha plus low-dose cytarabine: results from the IRIS study. J Clin Oncol. 2003; 21: 21382146.
  • 45
    Hughes TP,Branford S,Reynolds J, et al. Frequencies of major molecular responses to imatinib or interferon alfa plus low-dose cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 14211432.